Login / Signup

Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review.

Hanna SzmyginJoanna SzydełkoBeata Matyjaszek-Matuszek
Published in: Journal of clinical medicine (2022)
The exact mechanisms underlying dopamine agonists' resistance in lactotroph tumours are not fully understood, yet refractory prolactinomas pose a great challenge in everyday clinical practice. Several predictive factors that contribute to poor response to medical treatment have been identified, among them the elevated Ki-67 index. Recently, various alternative medical treatments have been considered, but their usefulness remains to be evaluated. A return of menses can serve as a first clinical indication of successful medical treatment.
Keyphrases
  • healthcare
  • clinical practice
  • uric acid
  • squamous cell carcinoma
  • combination therapy
  • metabolic syndrome
  • neoadjuvant chemotherapy
  • prefrontal cortex
  • replacement therapy